Co-founder and CEO of Seattle Genetics, Clay Siegall, is spearheading a groundbreaking initiative to introduce revolutionary biotechnology into the global pharmaceutical markets. Sally James discusses the far-reaching effects of these efforts in a recent article on Seattlebusinessmag.com. It appears that Siegall, who also acts as chairman of the board and president of the Washington based company, plans to use his extensive knowledge in the pharmaceutical industry to move his company into the next generation of biotechnological research. Seattle Genetics proves to be a company that cares about the future, with their specific interest in cancer drug formation. No doubt these efforts are bolstered by Siegall’s previous experience with Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. Seigall hopes to challenge the standard practices of his field by not only focusing on quality drug development but also tackling the difficulties of marketing such medications overseas in an international market.
Strengthening his positions held within Seattle Genetics, Seigall holds a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University. He uses his experience to advance his own and his company’s knowledge in the field of biotechnology. With over 70 publications and 15 patents, Seigall has proved his commitment to his work. In fact, Seattle Genetics has 11 cancer drugs poised to be released into international markets soon. Seigal expresses high hopes for four of them; Adcentris a treatment for Hodgkin’s lymphoma; 22ME for bladder cancer; 33A a treatment acute myeloid leukemia; and LIV1 a drug that is aimed at fighting breast cancer. Adcentris is an exciting prospect because if the tests, expected to conclude this year, show dramatic results the drug could be adopted as a primary therapy in the treatment of Hodgkin’s lymphoma. The success of this drug therapy will not only save countless lives, but it will also solidify Seattle Genetics as the powerhouse of biotechnological research that they are.
With a strong leader at the helm like Clay Seigall, it is not surprising that Seattle Genetics has risen to the call placed within the oncological community. Since the founding his company in 1998, Seigall has proved to be a formative man and an innovative leader. His commitment to his cause will not only lead to the successful international marketing of oncological medications but has Seattle Genetics poised to make a difference countless lives.